NCT04776018View on ClinicalTrials.gov

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

August 2, 2023

Study Completion Date

November 9, 2023

Conditions
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
DRUG

TAK-981

TAK-981 IV infusion.

DRUG

Mezagitamab

Mezagitamab SC injection.

DRUG

Daratumumab and Hyaluronidase-fihj

Daratumumab and Hyaluronidase-fihj SC injection.

Trial Locations (13)

10065

Weill Cornell Medical Center, New York

20817

American Oncology Partners of Maryland, PA, Bethesda

32224

Mayo Clinic Jacksonville - PPDS, Jacksonville

45220

TriHealth Cancer Institute, Cincinnati

46202

Indiana University, Indianapolis

53226

Medical College of Wisconsin Cancer Center, Milwaukee

55905

Mayo Clinic - Cancer Center - Rochester - PPDS, Rochester

68130

Oncology Hematology West (Omaha) - USOR, Omaha

75246

Baylor Sammons Cancer Center, Dallas

75702

Northeast Texas Cancer and Research Institute, Tyler

85259

Mayo Clinic Arizona - PPDS, Scottsdale

30322-1013

Winship Cancer Institute, Emory University, Atlanta

H1T 2M4

Hopital Maisonneuve-Rosemont, Montreal

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04776018 - A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) | Biotech Hunter | Biotech Hunter